1. Introduction

The regulation of National Immunization Biotech Innovation Programmes in Morocco involves the legal, scientific, administrative and institutional framework governing vaccine research, development, clinical testing, manufacturing, approval, distribution and public immunization.

Morocco's immunization policy aims to achieve several objectives:

Protect the population against vaccine-preventable infectious diseases.

Encourage domestic vaccine research and biotechnology innovation.

Develop national vaccine-manufacturing capacity.

Ensure the safety, efficacy and quality of vaccines.

Promote equitable access to immunization.

Strengthen national preparedness for epidemics and pandemics.

Protect patients participating in vaccine clinical trials.

Establish accountability for vaccine-related injuries and regulatory failures.

The subject is particularly important because Morocco is pursuing greater vaccine sovereignty and domestic pharmaceutical production while strengthening its regulatory institutions.

The legal framework combines the Constitution, pharmaceutical legislation, biomedical research legislation, public-health laws and personal-data protection rules.

2. Constitutional foundations of immunization programmes

The Moroccan Constitution of 2011 provides the foundation for public-health protection and government responsibility.

Important constitutional provisions include:

Article 31: Establishes the state's responsibility, together with public institutions and territorial authorities, to facilitate access to healthcare and medical treatment.

Article 21: Protects the right to security and personal safety.

Article 22: Protects physical and moral integrity and prohibits treatment that violates human dignity.

Article 24: Protects privacy.

Article 154: Establishes principles governing public services, including equal access, continuity, quality, transparency and accountability.

These constitutional principles have important consequences for immunization programmes.

For example, the government must consider the availability of vaccines in rural communities, ensure that public vaccination services operate effectively and protect individuals from unsafe medical products.

Similarly, biotechnology companies participating in national immunization programmes must comply with applicable regulatory requirements.

Legal significance: Immunization is not merely a medical activity. It is also an aspect of the state's responsibility to protect public health, individual integrity and equality of access to healthcare.

3. National Immunization Programme (PNI)

Après une résurgence inquiétante, le Maroc vaccine contre la rougeole | Le Télégramme

CALENDRIER Vaccinal au maroc 2023.pdf

MOROCCO-HEALTH-VACCINE-MEASLES

11

Morocco operates a National Immunization Programme, commonly known as the Programme National d'Immunisation (PNI).

The programme provides vaccination services through public primary healthcare facilities.

According to Morocco's official health information portal, the national programme provides 13 vaccines free of charge through public primary healthcare facilities, covering diseases including:

Tuberculosis.

Poliomyelitis.

Diphtheria.

Tetanus.

Pertussis.

Hepatitis B.

Haemophilus influenzae type B.

Measles.

Rubella.

Pneumococcal infections.

Rotavirus infections.

Cervical cancer prevention through HPV vaccination.

The Ministry of Health and Social Protection prepares the national vaccination schedule, while the National Scientific and Technical Advisory Committee on Vaccination provides scientific and technical guidance.

The committee considers epidemiological conditions, scientific developments and World Health Organization recommendations.

Sehati+1

Legal and regulatory importance

The PNI creates an institutional mechanism through which scientific innovations can become part of national healthcare policy.

A newly developed vaccine cannot automatically become part of the national programme simply because it demonstrates promising laboratory results. It must satisfy the relevant safety, efficacy, quality, authorization and public-health requirements.

4. Regulation under Law No. 17-04: Code of Medicines and Pharmacy

Law No. 17-04, promulgated on 22 November 2006, establishes the principal pharmaceutical regulatory framework.

It governs pharmaceutical products, pharmaceutical establishments, manufacturing, distribution and marketing authorization.

Vaccines fall within the broader regulatory framework applicable to medicines for human use.

The legislation is particularly important for national immunization biotechnology innovation because it regulates:

A. Manufacturing authorization

Vaccine manufacturers must comply with applicable pharmaceutical establishment requirements.

B. Quality assurance

Manufacturers must maintain appropriate production controls and quality-assurance systems.

C. Marketing authorization

Vaccines intended for commercial distribution must satisfy the applicable authorization requirements.

D. Manufacturing standards

Production must comply with applicable pharmaceutical and good manufacturing practice requirements.

E. Regulatory supervision

The competent authorities can exercise regulatory oversight over pharmaceutical products and manufacturing activities.

The Moroccan Ministry of Health identifies Law No. 17-04 and its implementing regulations, including Decree No. 2-14-841 concerning marketing authorization for medicines for human use, among the relevant regulatory instruments.

sante.gov.ma+1

5. The 2024 pharmaceutical reform and vaccine sovereignty

Major regulatory development

An important development occurred through Decree-Law No. 2.24.728 of 27 September 2024, which amended Law No. 17-04.

The reform introduced specific provisions concerning the official release of batches of vaccines and sera intended for human use.

The relevant provisions include Articles 17.1 to 17.4.

Their principal requirements are:

Review of manufacturing information and quality-control test results for individual vaccine batches.

Official certification of batches before packaging and marketing, where the procedure applies.

Application to domestically manufactured and imported vaccines.

A specific exemption for vaccine and serum batches acquired by Morocco through UNICEF.

Continued responsibility of pharmaceutical manufacturers and responsible pharmacists despite the issuance of batch-release certification.

The reform is significant because marketing authorization for a vaccine and official release of an individual batch are distinct regulatory safeguards.

In February 2025, the Ministry reported parliamentary adoption of legislation approving the pharmaceutical reform and highlighted its relationship with vaccine sovereignty and domestic manufacturing.

sante.gov.ma+2

Legal significance: The reform seeks to strengthen regulatory confidence in domestically manufactured and imported vaccines while supporting Morocco's ambition to develop its national vaccine industry.

6. Role of the Moroccan Medicines and Health Products Agency (AMMPS)

Pharmacie.ma : tout savoir sur le médicament et la pharmacie

pharmacie.ma

The Moroccan Medicines and Health Products Agency (AMMPS) plays an important role in pharmaceutical and vaccine regulation.

Its regulatory responsibilities include relevant functions concerning:

Pharmaceutical product quality.

Marketing authorization.

Vaccine manufacturing oversight.

Quality-control requirements.

Official vaccine-batch release.

Regulatory compliance.

Safety monitoring and pharmaceutical vigilance.

A significant recent development was the publication, on 9 February 2026, of the official guideline concerning the release of batches of vaccines and sera for human use.

The guideline aims to harmonize national batch-release practices, clarify responsibilities, improve safety and align regulatory procedures with applicable international standards.

It applies to vaccines and sera subject to the official batch-release procedure.

ammps.gov.ma+1

This development is particularly relevant to biotechnology innovation because new vaccine platforms require reliable quality-control systems before their products can enter national immunization programmes.

7. Regulation of vaccine research and clinical trials under Law No. 28-13

Law No. 28-13 concerning the protection of persons participating in biomedical research is another fundamental component of Morocco's immunization innovation framework.

The law seeks to ensure that biomedical research is conducted transparently and that research participants receive appropriate protection.

It covers biomedical research involving human participants, including relevant intervention-based research and clinical trials involving experimental medicines.

Its regulatory importance includes:

A. Informed consent

Research participants must receive appropriate information about the research and its risks before participating.

B. Ethical supervision

Biomedical research must comply with the applicable ethical review and authorization framework.

C. Participant protection

Researchers must respect participants' dignity, safety and rights.

D. Risk management

Research risks and potential benefits must be appropriately evaluated.

E. Research accountability

Sponsors and investigators must comply with their legal and professional obligations.

These safeguards are essential when conducting clinical trials involving:

mRNA vaccines.

Recombinant protein vaccines.

Viral-vector vaccines.

DNA vaccines.

Therapeutic vaccines.

Novel adjuvant technologies.

Vaccines targeting emerging infectious diseases.

Ma Loi+1

8. Regulation of biotechnology innovation and vaccine manufacturing

Media

Science of mRNA - Moderna

Quick takes: Chikungunya vaccine trial, Nipah research partnership, CDC vaccine advisers to meet | CIDRAP

10

National immunization innovation requires a regulatory framework capable of accommodating new vaccine technologies.

Morocco's pharmaceutical framework is relevant to several technological developments.

The regulatory challenge is to encourage technological development without weakening patient protection.

Important distinction: Morocco's general pharmaceutical legislation provides the basis for regulating these products. It should not be assumed that every emerging biotechnology platform has its own separate, comprehensive vaccine statute.

9. Regulation of vaccine safety and pharmacovigilance

Pharmacovigilance is an essential component of national immunization programmes.

It involves identifying, evaluating, understanding and preventing adverse reactions associated with medicines and vaccines.

The regulatory system should address:

Identification of adverse events following immunization.

Medical investigation of suspected vaccine reactions.

Reporting by healthcare professionals.

Analysis of safety signals.

Communication of newly identified risks.

Regulatory review of vaccine authorization.

Appropriate corrective measures when safety concerns arise.

An adverse event following immunization does not automatically establish that a vaccine caused the event.

Medical evidence, clinical assessment and causal evaluation are important in determining responsibility.

For example, if a patient develops a serious neurological condition after vaccination, the investigation may need to consider:

The vaccine's known safety profile.

The patient's medical history.

The timing of symptoms.

Alternative medical explanations.

Scientific evidence concerning causation.

Whether the vaccine was stored and administered correctly.

The regulatory objective is to ensure that innovation does not compromise public safety.

10. Regulation of immunization data and genetic information

Morocco's Law No. 09-08 of 18 February 2009 regulates the protection of individuals concerning the processing of personal data.

This legislation is especially important for modern immunization programmes because biotechnology research increasingly involves:

Genetic information.

Genomic sequencing.

Vaccine-response databases.

Electronic vaccination records.

Clinical-trial participant information.

Immunological biomarkers.

Adverse-event reporting databases.

Article 1 of Law No. 09-08 recognises health and genetic information as sensitive personal data.

Article 3 establishes important principles concerning lawful processing, specified purposes, proportionality, accuracy and data retention.

cndp.ma+1

Consequently, national immunization research programmes should address:

Informed data collection: Individuals should receive appropriate information concerning the collection and use of their personal information.

Data security: Research institutions must implement appropriate technical and organisational safeguards.

Research confidentiality: Access to identifiable medical and genetic information should be appropriately restricted.

International transfers: Cross-border transfers of personal information must comply with the applicable requirements of Law No. 09-08.

Secondary research: The use of vaccination records or genetic information for unrelated research purposes requires an appropriate legal basis.

This becomes particularly significant when Morocco collaborates with foreign pharmaceutical companies, international research institutions and vaccine-development organisations.

11. Public procurement and equitable access to vaccines

Public procurement is another major component of national immunization biotechnology programmes.

Morocco must balance several considerations:

Affordable vaccine procurement.

Reliable supply chains.

Quality and safety.

Domestic manufacturing capacity.

International procurement cooperation.

Distribution to rural and underserved populations.

The national immunization programme provides scheduled vaccines free of charge through public primary healthcare facilities.

Morocco also has a specific exemption from official batch-release certification for vaccine and serum batches purchased through UNICEF under the provisions introduced by the 2024 reform.

This exemption should not be interpreted as a general exemption from all pharmaceutical safety requirements.

Sehati+1

Legal issue: A government procurement contract cannot remove the manufacturer's statutory obligations concerning product quality, safety and applicable pharmaceutical standards.

12. Compulsory vaccination and public-health emergencies

Morocco has historical legislation addressing compulsory vaccination.

One important instrument is Dahir No. 1.72.165 of 27 July 1972 concerning compulsory smallpox vaccination and revaccination.

The legislation provides for compulsory vaccination measures in specified circumstances, including epidemic threats.

Historical legislation also addressed compulsory diphtheria vaccination for children and students up to 14 years of age.

These provisions demonstrate that Moroccan law has recognised vaccination as a public-health measure that can, under legally specified conditions, involve compulsory obligations.

However, the existence of historical compulsory-vaccination provisions does not establish that every vaccine introduced under the National Immunization Programme is automatically compulsory.

The legality of a contemporary compulsory vaccination measure must be examined in light of its statutory basis, constitutional protections, proportionality and the applicable public-health framework.

QanounAI+1

13. Regulation under the National Health System framework

Law No. 34-09 concerning the health system and healthcare provision established an important framework for organising healthcare services.

Law No. 06-22 concerning the National Health System is also relevant to the modern institutional organisation of Moroccan healthcare.

These laws are relevant to immunization programmes because vaccine innovation requires an effective healthcare delivery structure.

Their practical implications include:

Coordination between national and regional healthcare institutions.

Strengthening primary healthcare.

Improving access to preventive services.

Supporting healthcare infrastructure.

Improving public-health planning.

Promoting the quality and continuity of healthcare services.

The Ministry of Health's official legislative catalogue identifies both laws within the national health-system framework.

sante.gov.ma

14. Judicial decisions and case laws

Moroccan vaccine jurisprudence is particularly important when examining the liability of the government for injuries allegedly caused by vaccination.

One significant reported dispute concerns the AstraZeneca COVID-19 vaccine.

Case 1: AstraZeneca vaccine injury litigation – Administrative Court, 2024

Important Moroccan litigation

Court: Administrative Court, Rabat (reported in Moroccan media).

Decision: February 2024, according to subsequent reporting.

Facts:

A Moroccan woman brought proceedings against the state following serious health complications allegedly associated with an AstraZeneca COVID-19 vaccination.

The claimant reportedly suffered Guillain-Barré syndrome and neurological complications.

She sought compensation for the injury.

Legal issue:

Whether the Moroccan state could be held administratively liable for serious harm allegedly resulting from a vaccine that had received governmental authorization and was used in a national public-health programme.

Decision:

The first-instance administrative court reportedly awarded the claimant MAD 250,000 in compensation.

The court's reasoning, as reported by Moroccan media, included the proposition that state responsibility could arise from vaccination-related risks without requiring the claimant to establish administrative fault.

Legal significance:

The dispute raises important questions concerning:

State responsibility for public-health interventions.

Compensation for serious vaccine-related injuries.

The relationship between regulatory authorization and state liability.

Protection of individuals participating in national immunization campaigns.

The distinction between vaccine safety and individual adverse reactions.

Important qualification: The complete first-instance judgment has not been independently verified here. The reasoning described above is based on contemporary media reporting, not an authenticated judicial text.

HESPRESS English - Morocco News+1

Case 2: State of Morocco v. AstraZeneca vaccine claimant – Rabat Administrative Court of Appeal, 24 July 2024

Court: Rabat Administrative Court of Appeal.

Decision date: 24 July 2024.

Background:

Following the first-instance award of MAD 250,000, the Moroccan Ministry of Health appealed.

The appeal concerned the state's liability for the claimant's alleged vaccine-related neurological injury.

Decision:

The Court of Appeal reportedly overturned the first-instance judgment on 24 July 2024.

Legal significance:

The appellate outcome is particularly important because it demonstrates that compensation for vaccine-related injuries cannot be treated as automatically established merely because an injury occurred after vaccination.

The case raises questions concerning:

Medical causation.

The evidentiary burden in administrative liability.

State responsibility for vaccination programmes.

The distinction between regulatory authorization and compensation liability.

The legal consequences of reversing a first-instance compensation award.

Limitation: The full appellate judgment and its precise legal reasoning were not available in the reporting examined. It would therefore be inappropriate to attribute a particular legal test or detailed judicial finding to the appellate court.

Numéro un de l'information économique marocaine

Case 3: European Court of Human Rights – Vavřička and Others v. the Czech Republic (2021)

Court: European Court of Human Rights.

Citation: Applications Nos. 47621/13 and others, Grand Chamber judgment, 8 April 2021.

Facts:

The applicants challenged Czech childhood vaccination requirements and the consequences of non-compliance.

Legal issue:

Whether compulsory childhood vaccination arrangements violated Article 8 of the European Convention on Human Rights, which protects private life.

Decision:

The Grand Chamber found no violation of Article 8 in the circumstances of the cases.

Legal principles:

The Court recognised that vaccination requirements can serve legitimate public-health objectives.

It considered the protection of children and the broader population, the margin of appreciation available to states and the proportionality of the relevant measures.

Relevance to Morocco:

This decision is not binding Moroccan domestic precedent. Nevertheless, it offers a comparative human-rights framework for analysing compulsory vaccination, parental objections, public-health protection and proportionality.

It can inform legal scholarship concerning Morocco's immunization policies, subject to Morocco's own Constitution and applicable legislation.

15. Legal liability of vaccine manufacturers and research institutions

National immunization biotechnology programmes create different categories of legal responsibility.

Three important liability situations should be distinguished.

A. Manufacturing liability

A manufacturer may face legal consequences where a vaccine is improperly manufactured, contaminated or fails to satisfy applicable quality requirements.

B. Clinical research liability

A research sponsor or investigator may face legal consequences for violations of biomedical research requirements, including failures involving participant protection and informed consent.

C. Administrative liability

Public authorities may face proceedings where an unlawful administrative decision, failure of public-service obligations or other legally recognised basis of liability is established.

The existence of an adverse reaction alone does not automatically establish liability against every participant in the immunization programme.

16. International legal framework

Morocco's national immunization programmes operate within a broader international legal environment.

Important international instruments and standards include:

International Health Regulations (2005): Establish international public-health obligations concerning disease surveillance and responses to public-health emergencies.

WHO vaccine quality standards: Provide internationally recognised guidance for vaccine safety, quality and regulatory oversight.

Convention on the Rights of the Child: Provides a human-rights framework for children's health and access to healthcare.

International Covenant on Economic, Social and Cultural Rights: Article 12 recognises the right to the highest attainable standard of physical and mental health.

Convention on Biological Diversity: Relevant to biological resources and biodiversity-related biotechnology activities.

Nagoya Protocol: Relevant where vaccine research involves genetic resources and associated traditional knowledge within its scope.

International standards can assist Morocco in improving domestic vaccine regulation, scientific cooperation and manufacturing capacity.

However, international guidelines should be distinguished from binding domestic legislation and treaty obligations.

17. Major legal and regulatory challenges

Morocco's national immunization biotechnology framework faces several important challenges.

1. Domestic manufacturing capacity

Developing domestic vaccine manufacturing requires substantial investment in technology, scientific expertise and quality-control infrastructure.

2. Regulatory capacity

New vaccine platforms require specialised scientific and regulatory expertise.

3. Clinical-trial protection

Innovative vaccines must be tested through scientifically valid and ethically acceptable research procedures.

4. Vaccine injury compensation

The AstraZeneca litigation demonstrates the importance of clear legal rules governing compensation for alleged vaccine-related injuries.

5. Data protection

Genomic and immunological research creates risks involving sensitive personal information.

6. Rural healthcare inequality

Geographical and infrastructural inequalities can affect access to immunization services.

7. International technology transfer

Foreign partnerships must address intellectual property, licensing, manufacturing knowledge and regulatory compliance.

8. Supply-chain security

Temperature-controlled storage, transportation and product traceability are essential for vaccine quality.

18. Recommendations for strengthening Morocco's legal framework

Several reforms could strengthen the regulation of national immunization biotechnology innovation programmes.

A particularly useful reform would be establishing a transparent vaccine injury compensation mechanism with clearly defined eligibility criteria, medical assessment procedures and appeal rights.

This would help distinguish legitimate compensation claims from unsupported claims of causation.

19. Conclusion

The regulation of National Immunization Biotech Innovation Programmes in Morocco represents an important intersection of pharmaceutical law, biotechnology governance, constitutional law, administrative accountability and public-health regulation.

Law No. 17-04 provides the principal pharmaceutical regulatory foundation, while Law No. 28-13 protects individuals participating in biomedical research. Law No. 09-08 establishes important safeguards for personal and genetic information. The national health-system legislation supports the institutional delivery of immunization services.

The 2024 pharmaceutical reform and the February 2026 vaccine-batch-release guideline represent important developments in Morocco's efforts to strengthen vaccine quality assurance and domestic manufacturing capacity.

The AstraZeneca litigation of 2024 also demonstrates the importance of judicial oversight and legal accountability in national immunization programmes. The reversal of the first-instance compensation award highlights the need for careful examination of medical causation and administrative liability.

Ultimately, Morocco's regulatory objective should be to establish a system in which biotechnology innovation, vaccine sovereignty, scientific integrity, public access and individual rights operate together.

20. Important legal references and research sources

Useful primary and secondary sources:

Moroccan Ministry of Health – Pharmaceutical regulatory legislation.

Moroccan Ministry of Health – Health system legislation.

Law No. 28-13 – Biomedical research protection.

Law No. 09-08 – Personal data protection.

AMMPS – Vaccine batch-release guideline, February 2026.

Morocco – Official vaccination programme information.

AstraZeneca vaccine compensation appeal – July 2024.

Moroccan first-instance vaccine injury judgment – May 2024.

Academic note: The two 2024 AstraZeneca proceedings are the principal specifically identified Moroccan vaccine-liability decisions in the sources examined. Their full authenticated judgments should be obtained before using them as formal judicial citations in a dissertation or court submission. The European decision is comparative jurisprudence, not Moroccan case law.